Scioderm's SD-101 Receives Breakthrough Therapy Designation From FDA for Treatment of Epidermolysis Bullosa
5/6/2013 9:45:42 AM
More...
|
Raleigh Startup Scioderm Nets $9 Million
4/30/2013 8:59:35 AM
More...
|
Scioderm's SD-101 Receives Breakthrough Therapy Designation From FDA for Treatment of Epidermolysis Bullosa
4/29/2013 10:03:56 AM
More...
|
Scioderm Closes $16 Million in Series A Financing
4/26/2013 7:07:00 AM
More...
|
Scioderm's Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
2/14/2013 8:42:15 AM
More...
|
Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children With Epidermolysis Bullosa (EB)
6/20/2012 7:46:56 AM
More...
|